Combination of New Drug to Counter Lung Cancer

Combination of New Drug to Counter Lung CancerNon-small cell lung cancer (NSCLC) is the most common type of lung cancer. It usually grows and spreads more slowly than small cell lung cancer. Now the Cancer Research UK has called in a treatment trial of a drug, which would aim to observe how effective a combination of drugs is in tacking NSCLC. The investigation would be split in two stages and would take place across UK. NSCLC accounts for around 85% of lung cancer cases. The survival rates for people suffering from NSCLC are also low, but it is hoped that these trial would help in uplifting that number.

People with NSCLC and solid tumors were given the same treatment initially. In this trial the patients with solid tumors would be initially administered with vandetanib and an investigational drug called selumentinib. After that people with NSCLC would receive the same combination.

Chief Investigator of the study, Dr. Denis Talbot said, "Therapies for lung cancer often become ineffective because the disease becomes resistant to treatment". But there has been a decline in the number due to advancement in chemotherapy, radiotherapy and drugs, the introduction of screening and better delivery of cancer diagnosis and treatment by the NHS.